Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viral hepatitis.

Ricardo Marrero1, Eugene Schiff

  • 1Center for Liver Diseases, University of Miami School of Medicine, Miami, Florida 33136, USA.

Current Opinion in Gastroenterology
|October 13, 2006
PubMed
Summary
This summary is machine-generated.

Advances in viral hepatitis treatment include new vaccines for hepatitis A and B, and improved therapies like entecavir and pegylated interferon for hepatitis B and C, offering better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.

Hepatology (Baltimore, Md.)·2021
Same author

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.

Liver international : official journal of the International Association for the Study of the Liver·2019
Same author

Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.

Alimentary pharmacology & therapeutics·2018
Same author

Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C.

Liver international : official journal of the International Association for the Study of the Liver·2018
Same author

Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection.

Hepatology (Baltimore, Md.)·2018
Same author

Barriers to Hepatitis C Screening in a Minority Population: A Comparison of Hepatitis C and Human Immunodeficiency Virus Screening Rates at a Community STD Clinic in Miami, Florida.

Journal of community health·2017
Same journal

Endoscopic techniques to minimize gastroesophageal reflux during peroral endoscopic myotomy.

Current opinion in gastroenterology·2026
Same journal

Postendoscopy esophageal adenocarcinoma and neoplasia: current status and future directions.

Current opinion in gastroenterology·2026
Same journal

The complement system in inflammatory bowel disease: from early observations to emerging frontiers.

Current opinion in gastroenterology·2026
Same journal

Goblet cell-associated antigen passages in health and disease.

Current opinion in gastroenterology·2026
Same journal

Inflammatory bowel diseases 2026: form, function and therapeutic considerations for the epithelial barrier.

Current opinion in gastroenterology·2026
Same journal

Dietary protein as a regulator of colitis and colorectal cancer.

Current opinion in gastroenterology·2026
See all related articles

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Viral hepatitis remains a significant global health concern, impacting millions and necessitating advancements in diagnosis and treatment.
  • Optimal response to hepatitis A vaccination is achieved in chronic hepatitis patients prior to hepatic decompensation.
  • Current treatments for chronic hepatitis B and C show varying efficacy and resistance patterns.

Purpose of the Study:

  • To review recent significant advancements in the management and treatment of viral hepatitis.
  • To highlight novel vaccines and therapeutic agents for hepatitis A, B, and C.
  • To discuss the clinical implications of new treatment strategies and drug resistance.

Main Methods:

  • Review of recent clinical studies and therapeutic trials in viral hepatitis.

Related Experiment Videos

  • Analysis of vaccine efficacy and antiviral drug effectiveness.
  • Evaluation of treatment outcomes, including viral load reduction and resistance development.

    • Main Results:

    • A new triple antigen vaccine for hepatitis B virus (HBV) demonstrates enhanced protection.
    • Entecavir shows efficacy in reducing HBV DNA levels with slower rebound compared to lamivudine.
    • Pegylated interferon alfa-2a administered weekly is more effective than standard interferon alfa-2a for chronic hepatitis C (HCV).
    • Combination therapy of pegylated interferon and ribavirin is the most effective for chronic hepatitis C.

    Conclusions:

    • Recent therapeutic innovations offer improved outcomes for patients with viral hepatitis.
    • New vaccines and antiviral agents are crucial for managing hepatitis A, B, and C.
    • Understanding drug resistance and optimizing treatment regimens are key to combating viral hepatitis effectively.